Global Cell Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Cell Therapy Market is presumed to reach the market size of nearly USD 34.72 Billion by 2032 from USD 5.32 Billion in 2023 with a CAGR of 23.18% under the study period 2024-2032.

Cell therapy is a medical treatment that uses living cells to treat or prevent disease. This approach aims to replace or repair damaged cells, tissues, or organs by introducing healthy cells into a patient's body. This therapy encompasses various techniques, including stem cell therapy, where stem cells are employed to regenerate damaged tissues, and adoptive cell transfer, where modified immune cells target and destroy cancer cells. The therapy has applications across numerous fields, including oncology, hematology, and regenerative medicine. This therapy holds significant promise for treating previously incurable diseases and conditions by harnessing the body's regenerative abilities and enhancing the immune response. Ongoing research & clinical trials continue to advance the development and application of cell-based treatments.

MARKET DYNAMICS

The cell therapy market is experiencing substantial growth attributed to the increasing prevalence of chronic & degenerative diseases. Cell therapy offers potential treatments for conditions such as cancer, cardiovascular diseases, and neurological disorders, where traditional therapies may be insufficient. The growing patient population and the need for innovative treatment options drive demand for advanced cell-based therapies. Technological advancements represent a significant opportunity for market expansion. Innovations in cell processing, gene editing, and cell manufacturing technologies are enhancing the efficacy and safety of cell therapies. Techniques such as CRISPR-Cas9 gene editing and advanced cell culture methods are improving the precision and effectiveness of treatments, fostering market growth. The rise in personalized medicine is also influencing the market. This therapy allows tailored treatments based on individual patient profiles, enhancing treatment outcomes and minimizing adverse effects. This trend towards personalized approaches aligns with the increasing focus on customized healthcare solutions, creating new opportunities for market growth.

Expanding research and development activities in cell therapy drives innovation and market growth. Investment in clinical trials, collaborations between biotech companies and research institutions, and government funding for this therapy research are accelerating the development of new therapies and expanding the range of treatable conditions. Regulatory support and approvals for these therapy products further contribute to market growth. As regulatory agencies provide clearer pathways for approval and commercialization, cell-based therapies' development and market entry become more feasible, attracting investment and increasing the availability of advanced treatments. However, high development and manufacturing costs, complex regulatory requirements, and potential ethical concerns may restrain market growth. Cell therapies' long-term efficacy and safety challenges could also impact widespread adoption and market acceptance.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cell Therapy. The growth and trends of Cell Therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cell Therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy Type

Allogeneic Therapies (Stem Cell Therapies (Hematopoietic Stem Cell Therapies, Mesenchymal Stem Cell Therapies), Non-Stem Cell Therapies (Keratinocytes & Fibroblast-based Therapies, Others)
Autologous Therapies (Stem Cell Therapies (BM, Blood & Umbilical Cord-derived Stem Cells, Adipose Derived Cells, Others)
Non-Stem Cell Therapies (T-Cell Therapies (CAR T Cell Therapy, T Cell Receptor (TCR)-based), Others

By Therapeutic Area

Oncology
Cardiovascular Disease (CVD)
Musculoskeletal Disorders
Dermatology
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cell Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cell Therapy market include Novartis AG, Gilead Sciences Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc, JCR Pharmaceuticals Co. Ltd., JW Therapeutics, Atara Biotherapeutics, Anterogen Co. Ltd., Medipost, S.Biomedics. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11210718

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CELL THERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy Type
- 3.7.2 Market Attractiveness Analysis By Therapeutic Area
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CELL THERAPY MARKET ANALYSIS BY THERAPY TYPE

5.1. Overview By Therapy Type
5.2. Historical and Forecast Data Analysis By Therapy Type
5.3. Allogeneic Therapies (Stem Cell Therapies (Hematopoietic Stem Cell Therapies, Mesenchymal Stem Cell Therapies), Non-Stem Cell Therapies (Keratinocytes & Fibroblast-based Therapies, Others) Historic and Forecast Sales By Regions
5.4. Autologous Therapies (Stem Cell Therapies (BM, Blood & Umbilical Cord-derived Stem Cells, Adipose Derived Cells, Others) Historic and Forecast Sales By Regions
5.5. Non-Stem Cell Therapies (T-Cell Therapies (CAR T Cell Therapy, T Cell Receptor (TCR)-based), Others Historic and Forecast Sales By Regions

6. GLOBAL CELL THERAPY MARKET ANALYSIS BY THERAPEUTIC AREA

6.1. Overview By Therapeutic Area
6.2. Historical and Forecast Data Analysis By Therapeutic Area
6.3. Oncology Historic and Forecast Sales By Regions
6.4. Cardiovascular Disease (CVD) Historic and Forecast Sales By Regions
6.5. Musculoskeletal Disorders Historic and Forecast Sales By Regions
6.6. Dermatology Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL CELL THERAPY MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CELL THERAPY COMPANIES

8.1. Cell Therapy Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF CELL THERAPY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Novartis AG
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Gilead Sciences Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Bristol-Myers Squibb Company
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Johnson & Johnson Services Inc
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. JCR Pharmaceuticals Co. Ltd.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. JW Therapeutics
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Atara Biotherapeutics
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Anterogen Co. Ltd.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Medipost
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. S.Biomedics
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies